These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 9561340)

  • 21. Immunological intervention in endotoxin shock.
    Ziegler EJ
    Prog Clin Biol Res; 1988; 272():319-25. PubMed ID: 3293079
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide-based treatment of sepsis.
    Brandenburg K; Andrä J; Garidel P; Gutsmann T
    Appl Microbiol Biotechnol; 2011 May; 90(3):799-808. PubMed ID: 21369803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjunctive therapy for septic shock: a review of experimental approaches.
    Lynn WA; Cohen J
    Clin Infect Dis; 1995 Jan; 20(1):143-58. PubMed ID: 7727640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo.
    Jiang Z; Hong Z; Guo W; Xiaoyun G; Gengfa L; Yongning L; Guangxia X
    Int Immunopharmacol; 2004 Apr; 4(4):527-37. PubMed ID: 15099530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gram-negative bacterial sepsis and sepsis syndrome.
    Dunn DL
    Surg Clin North Am; 1994 Jun; 74(3):621-35. PubMed ID: 8197534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules.
    David SA
    J Mol Recognit; 2001; 14(6):370-87. PubMed ID: 11757070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiendotoxin activity of cationic peptide antimicrobial agents.
    Gough M; Hancock RE; Kelly NM
    Infect Immun; 1996 Dec; 64(12):4922-7. PubMed ID: 8945527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
    Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
    JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiendotoxin therapy in sepsis.
    Colletti RC; Dew RB; Goulart AE
    Crit Care Nurs Clin North Am; 1993 Jun; 5(2):345-54. PubMed ID: 8398040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sepsis--the Wayne State University Symposium--part III. Bacteremia and endotoxemia: a discussion of their roles in the pathophysiology of gram-negative sepsis.
    Sibbald WJ
    Heart Lung; 1976; 5(5):765-71. PubMed ID: 823128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insight in LPS antagonist.
    Ianaro A; Tersigni M; D'Acquisto F
    Mini Rev Med Chem; 2009 Mar; 9(3):306-17. PubMed ID: 19275723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of septic shock: implications for prevention and treatment.
    Calandra T
    J Chemother; 2001 Nov; 13 Spec No 1(1):173-80. PubMed ID: 11936363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrashort Antimicrobial Peptides with Antiendotoxin Properties.
    Chih YH; Lin YS; Yip BS; Wei HJ; Chu HL; Yu HY; Cheng HT; Chou YT; Cheng JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5052-6. PubMed ID: 26033727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
    Talan DA
    Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of an anti-endotoxin vaccine for sepsis.
    Cross AS
    Subcell Biochem; 2010; 53():285-302. PubMed ID: 20593272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis.
    Natanson C; Hoffman WD; Suffredini AF; Eichacker PQ; Danner RL
    Ann Intern Med; 1994 May; 120(9):771-83. PubMed ID: 8147551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in anti-endotoxin-IgG antibody and endotoxaemia in three cases of gram-negative septic shock.
    Barclay GR; Scott BB; Wright IH; Rogers PN; Smith DG; Poxton IR
    Circ Shock; 1989 Oct; 29(2):93-106. PubMed ID: 2582583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug evaluation: E-5564.
    Ondiveeran HK; Fox-Robichaud A
    IDrugs; 2004 Jun; 7(6):582-90. PubMed ID: 15197664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.